JNCE News and Press, Jounce Therapeutics Inc. From 03/02/22

- Continued execution on two proof-of-concept clinical trials for JTX-8064 and Vopratelimab, INNATE and SELECT, with clinical data on track for 2022 - - JTX-1484, a new antagonist antibody targeting LILRB4, enters IND-enabling activities representing the fifth internally discovere...

Jounce Therapeutics (NASDAQ:JNCE) is scheduled to announce Q4 earnings results on Wednesday, March 2nd, before market open. The consensus EPS Estimate is -$0.28 (-132.6% Y/Y) and the consensus Revenue Estimate is $12.31M (-80.3% Y/Y). Over the last 3 months, EPS estimates have seen 0 upw...

AMRX,ANF,OTCPK:ARNGF,ARVL,BWEN,DCI,DIN,DLTR,DY,GRUB,GSL,ICPT,INSW,INVZ,JNCE,MGIC,PDCO,PSFE For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Wednesday's open

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a novel immun...

CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2021 fi...

Jounce is making an attempt to renovate how we treat cancer by developing novel immunotherapies that could expand these treatments to new patients and tumor types. The company’s platform and R&D capabilities are impressive. If all goes well, Jounce could have several blockb...

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at the followin...

Image source: The Motley Fool. Jounce Therapeutics, inc (NASDAQ: JNCE) Q3 2021 Earnings Call Nov 5, 2021 , 2:00 p.m. ET Operator Continue reading For further details see: Jounce Therapeutics, inc (JNCE) Q3 2021 Earnings Call Transcript

Jounce Therapeutics, Inc. (JNCE) Q3 2021 Earnings Conference Call November 4, 2021 8:00 A.M. ET Company Participants Eric Laub - Investor Relations Richard Murray - Chief Executive Officer and President Beth Trehu - Chief Medical Officer Dmitri Wiederschain - Chief Scientific Officer Kim Drap...

Jounce Therapeutics (NASDAQ:JNCE): Q3 GAAP EPS of -$0.59 misses by $0.15. Ended the quarter with $249.0 million in cash, cash equivalents and investments. Press Release For further details see: Jounce Therapeutics EPS misses by $0.15